[Nuclear receptor PPAR and hepatology: pathophysiological and therapeutical aspects].
In last few years, the topic of nuclear receptor has been developed in the field of hepatology allowing envisaging therapeutic strategies for the most frequent chronic liver diseases. Peroxysome proliferator-activated receptors (PPAR) contribute to wide physiological processes within the liver such as lipid/glucid metabolisms, inflammatory response, cell differenciation and cell cycle. In vitro experiments and animal studies showed that PPARalpha discloses anti-inflammatory property and PPARgamma discloses anti-inflammatory, antifibrogenic and antiproliferative properties in the liver. Main available agonists are fibrates (PPARalpha) used for 20 years in cases of lipid metabolism abnormalities and glitazones (PPARgamma) used since 2000 for type 2 diabetes. In terms of therapy, animal studies and human trials have been conducted in steatopathies. However, clinicians have to be aware of potential specific side effects related to glitazones especially on cardiovascular system.
Dharancy
S
S
Inserm U795, Boulevard du Professeur-Jules-Leclercq, 59037 Lille, France. s6@chru-lille.fr
Louvet
A
A
Hollebecque
A
A
Desreumaux
P
P
Mathurin
P
P
Dubuquoy
L
L
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology; D002453:Cell Cycle / Q000187:drug effects; D006801:Humans; D007249:Inflammation / Q000503:physiopathology; D008107:Liver Diseases / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology*; D047495:PPAR gamma / Q000187:drug effects; D047492:Peroxisome Proliferator-Activated Receptors / Q000819:agonists*; D013844:Thiazoles / Q000494:pharmacology; D045162:Thiazolidinediones / Q000494:pharmacology*
D000970:Antineoplastic Agents; D047495:PPAR gamma; D047492:Peroxisome Proliferator-Activated Receptors; D013844:Thiazoles; D045162:Thiazolidinediones